Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q15408409> ?p ?o }
Showing triples 1 to 58 of
58
with 100 triples per page.
- Q15408409 subject Q6300308.
- Q15408409 subject Q7297892.
- Q15408409 subject Q8235435.
- Q15408409 subject Q8256003.
- Q15408409 subject Q8302165.
- Q15408409 subject Q8431759.
- Q15408409 subject Q8708271.
- Q15408409 abstract "EPI-001 is a novel experimental non-steroidal antiandrogen that is under investigation for the treatment of prostate cancer. The drug is being developed by the pharmaceutical company ESSA Pharma Inc (Vancouver, Canada) for the treatment of castration-resistant prostate cancer (CRPC) and is currently in pre-clinical development.EPI-001 is an antagonist of the androgen receptor (AR) that acts by binding covalently to the N-terminal domain (NTD) of the AR and blocking protein-protein interactions required for transcriptional activity of the AR and its splice variants (IC50 for inhibition of AR NTD transactivation ≈ 6 µM). This is different from all currently-used antiandrogens, which, conversely, bind to the C-terminal ligand-binding domain (LBD) of the AR and competitively block binding and activation of the receptor by androgens. Due to its unique mechanism of action, EPI-001 may prove to be effective in the treatment of advanced prostate cancer resistant to conventional antiandrogens such as enzalutamide.As of 2016, EPI-001's successor, EPI-506, is under clinical investigation in a phase I/II study.".
- Q15408409 iupacName "3-(4-{2-[4-(3-Chloro-2-hydroxypropoxy)phenyl]-2-propanyl}phenoxy)-1,2-propanediol".
- Q15408409 pubchem "4166922".
- Q15408409 thumbnail EPI-001.svg?width=300.
- Q15408409 wikiPageWikiLink Q1129238.
- Q15408409 wikiPageWikiLink Q1138899.
- Q15408409 wikiPageWikiLink Q14873015.
- Q15408409 wikiPageWikiLink Q14911859.
- Q15408409 wikiPageWikiLink Q177900.
- Q15408409 wikiPageWikiLink Q181257.
- Q15408409 wikiPageWikiLink Q1996756.
- Q15408409 wikiPageWikiLink Q20707196.
- Q15408409 wikiPageWikiLink Q2080808.
- Q15408409 wikiPageWikiLink Q20970208.
- Q15408409 wikiPageWikiLink Q21098941.
- Q15408409 wikiPageWikiLink Q21098975.
- Q15408409 wikiPageWikiLink Q235816.
- Q15408409 wikiPageWikiLink Q284398.
- Q15408409 wikiPageWikiLink Q286779.
- Q15408409 wikiPageWikiLink Q310425.
- Q15408409 wikiPageWikiLink Q321431.
- Q15408409 wikiPageWikiLink Q3271540.
- Q15408409 wikiPageWikiLink Q369310.
- Q15408409 wikiPageWikiLink Q391028.
- Q15408409 wikiPageWikiLink Q410943.
- Q15408409 wikiPageWikiLink Q422500.
- Q15408409 wikiPageWikiLink Q424197.
- Q15408409 wikiPageWikiLink Q5518498.
- Q15408409 wikiPageWikiLink Q55505.
- Q15408409 wikiPageWikiLink Q574820.
- Q15408409 wikiPageWikiLink Q62614.
- Q15408409 wikiPageWikiLink Q6300308.
- Q15408409 wikiPageWikiLink Q6581305.
- Q15408409 wikiPageWikiLink Q7239206.
- Q15408409 wikiPageWikiLink Q7297892.
- Q15408409 wikiPageWikiLink Q8235435.
- Q15408409 wikiPageWikiLink Q8256003.
- Q15408409 wikiPageWikiLink Q8302165.
- Q15408409 wikiPageWikiLink Q8431759.
- Q15408409 wikiPageWikiLink Q8708271.
- Q15408409 wikiPageWikiLink Q896177.
- Q15408409 iupacName "3".
- Q15408409 pubchem "4166922".
- Q15408409 type ChemicalSubstance.
- Q15408409 type Drug.
- Q15408409 type ChemicalObject.
- Q15408409 type Thing.
- Q15408409 type Q8386.
- Q15408409 comment "EPI-001 is a novel experimental non-steroidal antiandrogen that is under investigation for the treatment of prostate cancer.".
- Q15408409 label "EPI-001".
- Q15408409 depiction EPI-001.svg.